e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Antibiotics, resistance and vaccines
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Colistin therapy for nosocomial pneumonia and nephrotoxicity
P. Ekren, Z. N. Töreyin, A. çeltik, H. Pullukçu, A. Gürgün, H. Uluer, F. Bacakoglu, S. S. Aydemir, A. Sayiner (Izmir, Turkey)
Source:
Annual Congress 2013 –Antibiotics, resistance and vaccines
Session:
Antibiotics, resistance and vaccines
Session type:
Thematic Poster Session
Number:
2749
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Ekren, Z. N. Töreyin, A. çeltik, H. Pullukçu, A. Gürgün, H. Uluer, F. Bacakoglu, S. S. Aydemir, A. Sayiner (Izmir, Turkey). Colistin therapy for nosocomial pneumonia and nephrotoxicity. Eur Respir J 2013; 42: Suppl. 57, 2749
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia?
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Treatment of nosocomial pneumonia with piperacillin-tazobactam
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007
Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia
Source: Annual Congress 2013 –Recent developments in pneumonia
Year: 2013
Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016
Development of an antibody therapy for the treatment of pneumonia
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Health care-associated pneumonia and community-acquired pneumonia: A single-center experience
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015
Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms
Source: Eur Respir J 2007; 30: 307-313
Year: 2007
Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Pseudomonas aeruginosa
pneumonia in the community
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
New antibiotics for VAP
Source: Eur Respir Mon 2011; 53: 48-53
Year: 2011
Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept